drugset / Trial / NCT02908477

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

NCT02908477 ↗

Phase 3 Completed 228 enrolled Mayo Clinic
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy. This study investigates a less intense radiation treatment following surgery that uses half the dose of radiation given over two weeks rather than six weeks. Patients will be randomly assigned to receive the less intense treatment versus the traditional treatment by coin flip. Patients are twice as likely to receive the less intense treatment during randomization.

Timeline

Start
2016-10-03
Primary completion
2022-08-20
Completion
2024-11-15

Outcome

Met primary endpoint

paper 3% (four of 125 patients) in the de-escalated adjuvant radiotherapy group and 11% (seven of 62 patients) in the standard of care group (p=0·042) PMID 40907518 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 40 mg/m2 Intravenous
Subject Docetaxel Small molecule 15 mg/m2 Intravenous

Indications